Charles Wykoff

Dr. Charles Wykoff

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in The Lancet
Verified
Journal Article
Closed access
JHJeffrey S Heier
Jeffrey S Heier
ELEleonora M Lad
Eleonora M Lad
FHFrank G Holz
Frank G Holz
PRPhilip J Rosenfeld
Philip J Rosenfeld
RGRobyn H Guymer
Robyn H Guymer
OIOAKS and DERBY study investigators
OAKS and DERBY study investigators

24 January 2022 in The Lancet
Verified
Journal Article
Closed access
CWCharles Wykoff
Charles Wykoff
FAFrancis Abreu
Francis Abreu
AAAnthony P Adamis
Anthony P Adamis
KBKaren Basu
Karen Basu
DEDavid A Eichenbaum
David A Eichenbaum
YIYOSEMITE and RHINE Investigators
YOSEMITE and RHINE Investigators

1 August 2019 in Ophthalmology
Verified
Journal Article
Open access
JSJayashree Sahni
Jayashree Sahni
SPSunil S. Patel
Sunil S. Patel
PDPravin U. Dugel
Pravin U. Dugel
AKArshad M. Khanani
Arshad M. Khanani
CJChirag D. Jhaveri
Chirag D. Jhaveri
SFSascha Fauser
Sascha Fauser
The phase 2 BOULEVARD trial compared safety and efficacy of faricimab, a novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor-A (VEGF-A), with ranibizumab in patients with diabetic macular edema (DME). The BOULEVARD trial (ClinicalTrials.gov identifier, NCT02699450) was a prospective, randomized, active comparator-controlled, double-masked, multicenter, phase 2 study conducted at 59 sites in the United States. The trial enrolled patients 18 years of age or older with center-involving DME, best-corrected visual acuity (BCVA) of 73 to 24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and central subfield thickness (CST) of 325 μm or more. Anti-VEGF treatment-naïve patients were randomized 1:1:1 to intravitreal 6.0 mg faricimab, 1.5 mg faricimab, or 0.3 mg ranibizumab, and patients previously treated with anti-VEGF were randomized 1:1 to 6.0 mg faricimab or 0.3 mg ranibizumab. Patients were dosed monthly for 20 weeks, followed by an observation period up to week 36 to assess durability. The prespecified primary outcome measure was mean change in BCVA from baseline at week 24 for faricimab versus ranibizumab in treatment-naïve patients. Key secondary and exploratory outcome measures included CST, Diabetic Retinopathy Severity Scale (DRSS) score, and durability as assessed by time to re-treatment. The trial enrolled 229 patients (168 treatment-naïve and 61 previously treated with anti-VEGF). In treatment-naïve patients, 6.0 mg faricimab, 1.5 mg faricimab, and 0.3 mg ranibizumab resulted in mean improvements of 13.9, 11.7, and 10.3 ETDRS letters from baseline, respectively. The 6.0-mg faricimab dose demonstrated a statistically significant gain of 3.6 letters over ranibizumab (P = 0.03). In both patient populations, faricimab resulted in dose-dependent reductions in CST, improvements in DRSS score, and longer time to re-treatment during the observation period compared with ranibizumab. Faricimab showed no new or unexpected safety signals. The BOULEVARD trial met its primary end point; faricimab demonstrated statistically superior visual acuity gains versus ranibizumab at week 24 in treatment-naïve patients. Central subfield thickness reduction, DRSS score improvement, and extended durability outcomes support the primary outcome. These findings suggest the benefit of simultaneous inhibition of angiopoietin-2 and VEGF-A with faricimab for patients with DME.

1 December 2015 in Ophthalmology
Verified
Journal Article
Open access
CWCharles Wykoff
Charles Wykoff
DCDaniel E. Croft
Daniel E. Croft
DBDavid M. Brown
David M. Brown
RWRui Wang
Rui Wang
JPJohn F. Payne
John F. Payne
SSSriniVas R. Sadda
SriniVas R. Sadda
To assess prospectively a treat-and-extend (TREX) management strategy compared with monthly dosing of intravitreal ranibizumab in treatment-naïve neovascular age-related macular degeneration (AMD) patients. Phase IIIb, multicenter, randomized, controlled clinical trial. Sixty patients with treatment-naïve neovascular AMD randomized 1:2 to monthly or TREX management. Patients with Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) from 20/32 to 20/500 (Snellen equivalent) were randomized to receive intravitreal 0.5 mg ranibizumab monthly or according to a TREX protocol. The TREX patients were treated monthly for at least 3 doses, until resolution of clinical and spectral-domain optical coherence tomography evidence of exudative disease activity; the interval between visits then was individualized according to a strict prospective protocol. Mean ETDRS BCVA change from baseline. At baseline, mean age was 77 years (range, 59-96 years), mean BCVA was 20/60 (Snellen equivalent), and mean central retinal thickness (CRT) was 511 μm. Fifty-seven eyes (95%) completed month 12, at which point mean BCVA improved by 9.2 and 10.5 letters in the monthly and TREX cohorts, respectively (P = 0.60). The mean number of injections administered through month 12 was 13.0 and 10.1 (range, 7-13) in the monthly and TREX cohorts, respectively (P < 0.0001). Among TREX patients, 7 (18%) were maximally extended, 4 (10%) demonstrated fluid at every visit, and at month 12, 18 (45%) had achieved an extension interval of 8 weeks or more; the mean maximum extension interval between injections after the first 3 monthly doses was 8.4 weeks (range, 4-12 weeks). Most TREX patients who demonstrated recurrent exudative disease activity (17/24 [71%]) were unable to extend beyond their initial maximum extension interval. The TREX neovascular AMD management strategy used in this prospective, randomized, controlled trial resulted in visual and anatomic gains comparable with those obtained with monthly dosing.

1 September 2021 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
DBDavid M. Brown
David M. Brown
CWCharles Wykoff
Charles Wykoff
DBDavid Boyer
David Boyer
JHJeffrey S. Heier
Jeffrey S. Heier
WCW. Lloyd Clark
W. Lloyd Clark
RVRobert Vitti
Robert Vitti
Diabetic retinopathy (DR) is a leading cause of blindness globally.1,2 Disease severity ranges from nonproliferative DR (NPDR) to proliferative DR (PDR), with 13 distinct categories on the Diabetic Retinopathy Severity Scale (DRSS) developed in the Early Treatment Diabetic Retinopathy Study (ETDRS).3 The microvascular ischemia associated with DR leads to vision loss, primarily through pathologic neovascularization of the retina and/or anterior segment and diabetic macular edema (DME). Increasing NPDR severity is associated with an increased risk of progression to PDR and vision loss.3

20 January 2021 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
CWCharles Wykoff
Charles Wykoff
RKRahul N. Khurana
Rahul N. Khurana
QNQuan Dong Nguyen
Quan Dong Nguyen
SKScott P. Kelly
Scott P. Kelly
FLFlora Lum
Flora Lum
VGVincent Garmo
Vincent Garmo
OBJECTIVE: To evaluate the association between initial diabetic retinopathy (DR) severity/risk of blindness in patients with newly diagnosed DR/good vision in the U.S.RESEARCH DESIGN AND METHODS: This retrospective cohort study evaluated adult patients with good vision (20/40 or better) and newly diagnosed DR between 1 January 2013 and 31 December 2017 (index date) in the American Academy of Ophthalmology’s Intelligent Research in Sight (IRIS) Registry. The primary exposure of interest was DR severity at index: mild nonproliferative DR (NPDR), moderate NPDR, severe NPDR, and proliferative DR (PDR). The main outcome measure was development of sustained blindness (SB), defined as study eyes with Snellen visual acuity readings of 20/200 or worse at two separate visits ≥3 months apart that did not improve beyond 20/100.RESULTS: Among 53,535 eligible eyes (mean follow-up 662.5 days), 678 (1.3%) eyes developed SB. Eyes with PDR at index represented 10.5% (5,629 of 53,535) of the analysis population but made up 26.5% (180 of 678) of eyes that developed SB. Kaplan-Meier analysis revealed that eyes with moderate NPDR, severe NPDR, and PDR at index were 2.6, 3.6, and 4.0 times more likely, respectively, to develop SB after 2 years of DR diagnosis versus eyes with mild DR at index. In a Cox proportional hazards model adjusted for index characteristics/development of ocular conditions during follow-up, eyes with PDR had an increased risk of developing SB versus eyes with mild NPDR at index (hazard ratio 2.26 [95% CI 2.09−2.45]).CONCLUSIONS: In this longitudinal ophthalmologic registry population involving eyes with good vision, more advanced DR at first diagnosis was a significant risk factor for developing SB.